Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Intuitive Surgical, Inc.

ISRG
Healthcare · Medical Instruments & Supplies

Intuitive Surgical, Inc.'s earnings have outrun its stock. EPS grew +22.6% in a year against a −23.8% price move.

The sharpest disagreement: annual EPS moved +22.6% against a −23.8% price move — the market has not yet caught up with the delivery.

The price is in a downtrend (28 weeks in) while the P/E sits at the 1st percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +18.6% year on year, and 103% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.

Stage
Consistent
fundamental trajectory, 12 quarters
Price
$368
−23.8% 1Y
P/E
42.2×
1st pctile
of its own 4-year range
Revenue (Mar 26)
$2.8 B
+23.1% YoY
Profit (Mar 26)
$0.8 B
+18.6% YoY
Operating margin
31.0%
+5.2 pp YoY
ROE
17%
FY25
ROIC
21.9%
vs WACC 12.3% → +9.6 pp
Cash conversion
103%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Intuitive Surgical, Inc. trades at $368, in a downtrend and 28 weeks into that stage. That is −23.5% against its own 200-day average. It sits at 12% of a 52-week range of $338 to $586. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (29 weeks and counting).

Today the stock is in a downtrend — week 28 of stage 4. At $368 it trades −23.5% versus its 200-day average and sits at 12% of its 52-week range ($338–$586).

Aug 26: $368 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
−23.5% versus the 200-day line, week 28 of stage 4
Price50-day avg200-day avg
S2S2S1S3S4$622$525$427$330$232$$368$481Jul 23Apr 24Jan 25Oct 25Aug 26
S2S2S1S3S4$622$525$427$330$232$$368$481Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (527 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Aug 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +388% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (29 weeks and counting; last ahead the week of 2026-01-16) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Intuitive Surgical, Inc. trades at 42.2× P/E, about the cheapest it has ever traded. Its long-run median P/E is 71.7×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 42.2× is about the cheapest it has ever traded, against a long-run median of 71.7× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 42.2× vs a 71.7× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 4.3-year window; loss-period spikes above 91× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
about the cheapest it has ever traded
P/EMedianEPS (TTM) (quarterly)
95.0×$8.980.5×$6.766.0×$4.551.4×$2.236.9×$0.0×$44.64×$8Apr 22Apr 23May 24Jul 25Aug 26
95.0×$8.980.5×$6.766.0×$4.551.4×$2.236.9×$0.0×$44.64×$8Apr 22May 24Aug 26
PEG 2.44 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 20 quarters.
above 1.0, the multiple already banks the growth
PEGPEG = 1.0
5.3×4.2×3.0×1.8×0.7××2.44×Sep 21Sep 22Dec 23Mar 25Jun 26
5.3×4.2×3.0×1.8×0.7××2.44×Sep 21Dec 23Jun 26
P/E
42.2×
1st percentile of 4y
PEG
2.07
as reported

Why the multiple sits where it does: over the past year annual EPS moved +22.6% against a −23.8% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 3y, of the +6.0%/yr price move, ~+27.4%/yr came from earnings growth and ~−21.4 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Consistent

Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Intuitive Surgical, Inc. reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 17.9% and holding. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +20.5% in FY25, profit +23.1% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
21%43%18%25%15%7.6%11%−9.8%8.0%−27%%%20.5%23.1%FY21FY23FY25
21%43%18%25%15%7.6%11%−9.8%8.0%−27%%%20.5%23.1%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising, profit stabilising
RevenueProfitEPS
23%56%20%41%17%26%14%11%11%−4.1%%%21.6%20.5%21%Jun 23Sep 24Mar 26
23%56%20%41%17%26%14%11%11%−4.1%%%21.6%20.5%21%Jun 23Sep 24Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
18%17%15%14%13%%17.9%Jun 23Dec 23Sep 24Jun 25Mar 26
18%17%15%14%13%%17.9%Jun 23Sep 24Mar 26
Revenue growth
Steady high
latest +21.6% · span +12.1% to +22.1%
Profit growth
Steady high
latest +20.5% · span +0.0% to +51.1%
EPS growth
Steady high
latest +21.0% · span +1.5% to +51.4%
ROCE
Steady high
latest 17.9% · span 13.0%–17.9%

Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+20.5%+17.4%
Profit+23.1%+29.1%
EPS+22.6%+29.2%
Stock price−23.8%+6.0%+1.4%+16.9%
Revenue YoY (Mar 26)
+23.1%
latest quarter vs a year ago
Profit YoY (Mar 26)
+18.6%
latest quarter vs a year ago
Revenue 10y
15.2%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

49.2/100 — rank 10 of 30 in Medical Instruments & Supplies · 58% evidence confidence

Intuitive Surgical, Inc. scores 49.2 out of 100 against the 30 companies it is compared with in Medical Instruments & Supplies, ranking 10. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 22.1 + 17 + 9.7 + 0.4 = 49.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Intuitive Surgical, Inc. reported $2.8 B of revenue in the Mar 26 quarter, +23.1% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 15.2% a year. The last full year, FY25, came in at $10.1 B. The last four reported quarters add to $10.6 B.

FY25 revenue came in at $10.1 B (+20.5% on the year), capping 4 years at 15.2% compound. The latest quarter (Mar 26) printed $2.8 B, +23.1% year on year — the 12th consecutive quarter of year-over-year growth.

FY25 revenue $10.1 B (+20.5% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
15.2% a year over 4 years
RevenueYoY growth
1121%8.118%5.415%2.711%0.08.0%$ B%$10B20.5%FY21FY23FY25
1121%8.118%5.415%2.711%0.08.0%$ B%$10B20.5%FY21FY23FY25
Mar 26: $2.8 B (+23.1% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
12th straight quarter of growth
Revenue (quarterly)YoY growth
3.126%2.322%1.518%0.814%0.010%$ B%$3B23.1%Jun 23Sep 24Mar 26
3.126%2.322%1.518%0.814%0.010%$ B%$3B23.1%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +21.6% growth against the decade's 15.2% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +21.6% over the last 4 quarters against +20.3%/yr over the last 8 — stabilising; TTM profit +20.5% vs +22.2%/yr — stabilising.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Intuitive Surgical, Inc.'s operating margin is 31.0% in the Mar 26 quarter, +5.2 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 24.9% to 31.9%. The current quarter sits inside that band.

The latest quarter's operating margin is 31.0%, +5.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 24.9%–31.9%.

Why the margin moved: operating margin went +5.2 pp year on year while gross margin went +1.2 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY25: 29.3% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a 24.9–31.9% band over 5 years
operating marginYoY change (pp)
32%4.0%30%1.2%28%−1.6%26%−4.5%24%−7.3%%%29.3%1.2%FY21FY23FY25
32%4.0%30%1.2%28%−1.6%26%−4.5%24%−7.3%%%29.3%1.2%FY21FY23FY25
Mar 26: 31.0% operating margin (+5.2 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
32%7.6%29%5.5%27%3.3%25%1.2%23%−0.9%%%31%5.2%Jun 23Sep 24Mar 26
32%7.6%29%5.5%27%3.3%25%1.2%23%−0.9%%%31%5.2%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Intuitive Surgical, Inc. earned $0.8 B of net profit in the Mar 26 quarter, +18.6% year on year. It is the 12th consecutive quarter of growth. Full-year FY25 profit was $2.9 B. The 4-year compound rate is 13.6%. That is 30.0% of the quarter's revenue. The same quarter a year earlier earned $0.7 B.

Mar 26 profit was $0.8 B, +18.6% year on year — the 12th consecutive quarter of growth. On the full year, FY25 printed $2.9 B (+23.1%), and the 4-year compound rate is 13.6%.

FY25 profit $2.9 B (+23.1% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
13.6% a year over 4 years
Net profitYoY growth
3.140%2.324%1.66.6%0.8−10%0.0−27%$ B%$3B23.1%FY21FY23FY25
3.140%2.324%1.66.6%0.8−10%0.0−27%$ B%$3B23.1%FY21FY23FY25
Mar 26: $0.8 B (+18.6% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
12th straight quarter of growth
Net profit (quarterly)YoY growth
0.985%0.765%0.446%0.227%0.07.8%$ B%$1B18.6%Jun 23Sep 24Mar 26
0.985%0.765%0.446%0.227%0.07.8%$ B%$1B18.6%Jun 23Sep 24Mar 26

Why profit moved: revenue contributed +23.1% and the margin +5.2 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +20.9% vs revenue +21.6%. Profit and revenue are moving roughly in step.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 103% of Intuitive Surgical, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $3.0 B of operating cash against $2.9 B of profit. After $0.5 B of capital spending, $2.5 B was left as free cash.

FY25: operating cash of $3.0 B against reported profit of $2.9 B, leaving free cash of $2.5 B after $0.5 B of capital spending. Across the last 3 fiscal years the conversion rate is 103% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $3.0 B vs profit $2.9 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
103% of 3-year profit arrived as cash
Operating cashNet profitFree cash
3.32.51.60.80.0$ B$3B$3B$3BFY21FY23FY25
3.32.51.60.80.0$ B$3B$3B$3BFY21FY23FY25
Jun 26: operating cash $1.1 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
1.1138%0.9111%0.685%0.358%0.031%$ B%$1B110%Sep 23Dec 24Jun 26
1.1138%0.9111%0.685%0.358%0.031%$ B%$1B110%Sep 23Dec 24Jun 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Intuitive Surgical, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $3.0 B over the last 3 years. Averaged over those years that is 9.9% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $3.0 B over the last 3 fiscal years.

FY25: capex $0.5 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
1.20.90.60.30.0$ B$1BFY21FY23FY25
1.20.90.60.30.0$ B$1BFY21FY23FY25
Jun 26: capex $0.1 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.51.00.40.70.20.40.10.00.0−0.3$ B$ B$0B$1BSep 23Dec 24Jun 26
0.51.00.40.70.20.40.10.00.0−0.3$ B$ B$0B$1BSep 23Dec 24Jun 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Intuitive Surgical, Inc. earns a ROE of 16% in FY25. That is up from a trough of 12% in FY22. Return on invested capital clears the cost of that capital by +9.6 percentage points, so growth here adds value rather than only size. The wiring behind it is 28.6% net margin on 0.49× asset turns.

FY25 ROE is 16%, recovered from a FY22 trough of 12% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 28.6% net margin × 0.49× asset turns × 1.14× balance-sheet leverage ≈ 16.0% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 21.9% − 12.3% = a +9.6 pp spread. The 12.3% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.

FY25: ROE 16% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 12.3% cost of capital used on this page.
the climb back from FY22's 12%
ROEROIC (annual)WACC
28%24%20%15%11%%16.1%20.9%FY21FY23FY25
28%24%20%15%11%%16.1%20.9%FY21FY23FY25
Jun 26: ROIC 22.9% (TTM) vs WACC 12.3% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
26%22%19%15%11%%22.9%18.1%Sep 23Dec 24Jun 26
26%22%19%15%11%%22.9%18.1%Sep 23Dec 24Jun 26
11 · Dividend

Dividend

Intuitive Surgical, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Intuitive Surgical, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

A borrowings history is not in our numbers for this stock.

A borrowings history is not in our numbers for this stock, so this section says that plainly rather than working around it.

13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

1.9% of Intuitive Surgical, Inc.'s tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 2.4 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 1.9% of the float is sold short, and at typical trading volumes it would take about 2.4 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
1.9%
of the tradable float
Days to cover
2.4
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Intuitive Surgical, Inc.: the Z-score reads 42.45. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 42.45 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 42.45.

15 · Related companies · Medical Instruments & Supplies
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1LeMaitre Vascular, Inc.LMAT 61.8/100Mixed-positive evidence81% evidence BASING 26.4/35 Revenue 12.8% · PAT 40% · OPM change 5.6 pp 83% evidence 16.2/25 ROCE 3.2% · OPM 26.7% 76% evidence 13.8/20 P/E 40.3× · PEG 1.09 65% evidence 5.4/20 RS sector -5.2% · RS bench -0.3% · 1Y 14.6%0 of 12 weeks ahead 100% evidence
Exact sum: 26.4 + 16.2 + 13.8 + 5.4 = 61.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -5.2% and the one-year return is 14.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
2West Pharmaceutical Services, Inc.WST 60.6/100Thin evidence · provisional58% evidence FADING 21.5/35 Revenue — · PAT — · OPM change 5.7 pp 45% evidence 17.1/25 ROCE 5.3% · OPM 21% 76% evidence 9.6/20 P/E 46× · PEG — 15% evidence 12.4/20 RS sector 6.1% · RS bench 11.8% · 1Y 44.7%10 of 12 weeks ahead 100% evidence
Exact sum: 21.5 + 17.1 + 9.6 + 12.4 = 60.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
3Baxter International Inc.BAX 57.3/100Thin evidence · provisional58% evidence BREAKING OUT 17.6/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence 10.0/25 ROCE 1.3% · OPM 2.4% 76% evidence 10.2/20 P/E 39.6× · PEG — 15% evidence 19.5/20 RS sector 18.6% · RS bench 24.1% · 1Y 19.7%9 of 12 weeks ahead 100% evidence
Exact sum: 17.6 + 10 + 10.2 + 19.5 = 57.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
4Avantor, Inc.AVTR 56.6/100Thin evidence · provisional58% evidence BREAKING OUT 15.4/35 Revenue — · PAT — · OPM change -3 pp 45% evidence 11.3/25 ROCE 1.2% · OPM 6.3% 76% evidence 11.3/20 P/E 13.6× · PEG — 15% evidence 18.6/20 RS sector 8.9% · RS bench 13.4% · 1Y 19%9 of 12 weeks ahead 100% evidence
Exact sum: 15.4 + 11.3 + 11.3 + 18.6 = 56.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
5ResMed Inc.RMD 55.5/100Mixed-positive evidence81% evidence TURNING 22.6/35 Revenue 10.3% · PAT 15.8% · OPM change 1.9 pp 83% evidence 17.6/25 ROCE 7.1% · OPM 34.9% 76% evidence 13.5/20 P/E 21.6× · PEG 1.32 65% evidence 1.8/20 RS sector -20.3% · RS bench -16.8% · 1Y -21.4%0 of 12 weeks ahead 100% evidence
Exact sum: 22.6 + 17.6 + 13.5 + 1.8 = 55.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Merit Medical Systems, Inc.MMSI 54.3/100Thin evidence · provisional58% evidence TURNING 18.8/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence 14.8/25 ROCE 2.4% · OPM 11.6% 76% evidence 10.5/20 P/E 28.7× · PEG — 15% evidence 10.2/20 RS sector -5.8% · RS bench -1.6% · 1Y 0.3%2 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 14.8 + 10.5 + 10.2 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7Solventum CorporationSOLV 50.9/100Mixed-positive evidence71% evidence BREAKING OUT 16.7/35 Revenue -0.6% · PAT 100% · OPM change -3.3 pp 83% evidence 11.3/25 ROCE 0.7% · OPM 4% 76% evidence 11.4/20 P/E 8× · PEG — 15% evidence 11.5/20 RS sector 0% · RS bench 4.9% · 1Y 19.8%9 of 12 weeks ahead 100% evidence
Exact sum: 16.7 + 11.3 + 11.4 + 11.5 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Envista Holdings CorporationNVST 50.7/100Thin evidence · provisional58% evidence TURNING 19.0/35 Revenue — · PAT — · OPM change 2.1 pp 45% evidence 11.4/25 ROCE 1.2% · OPM 8.9% 76% evidence 9.3/20 P/E 63× · PEG — 15% evidence 11.0/20 RS sector 0.4% · RS bench 5.6% · 1Y 38.1%1 of 12 weeks ahead 100% evidence
Exact sum: 19 + 11.4 + 9.3 + 11 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9AtriCure, Inc.ATRC 50.6/100Thin evidence · provisional52% evidence BREAKING OUT 21.4/35 Revenue — · PAT — · OPM change 5.2 pp 45% evidence 9.1/25 ROCE 1.7% · OPM 0.4% 76% evidence 9.0/20 P/E 133.2× · PEG — 15% evidence 11.1/20 RS sector -1.4% · RS bench 2.9% · 1Y 10.5%5 of 12 weeks ahead 70% evidence
Exact sum: 21.4 + 9.1 + 9 + 11.1 = 50.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
10Intuitive Surgical, Inc.this pageISRG 49.2/100Thin evidence · provisional58% evidence ASLEEP 22.1/35 Revenue — · PAT — · OPM change 5.2 pp 45% evidence 17.0/25 ROCE 5.2% · OPM 30.9% 76% evidence 9.7/20 P/E 45.6× · PEG — 15% evidence 0.4/20 RS sector -33.7% · RS bench -30.6% · 1Y -21.7%0 of 12 weeks ahead 100% evidence
Exact sum: 22.1 + 17 + 9.7 + 0.4 = 49.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11STAAR Surgical CompanySTAA 49.0/100Thin evidence · provisional52% evidence ASLEEP 23.7/35 Revenue — · PAT — · OPM change 76.1 pp 45% evidence 12.0/25 ROCE 2% · OPM 8.5% 76% evidence 9.1/20 P/E 84.6× · PEG — 15% evidence 4.2/20 RS sector -17.3% · RS bench -12.9% · 1Y -11.5%7 of 12 weeks ahead 70% evidence
Exact sum: 23.7 + 12 + 9.1 + 4.2 = 49 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12ICU Medical, Inc.ICUI 48.7/100Mixed-negative evidence64% evidence BREAKING OUT 14.1/35 Revenue -10.9% · PAT — · OPM change 0.5 pp 62% evidence 7.8/25 ROCE 0.4% · OPM 2.6% 76% evidence 9.2/20 P/E 69.8× · PEG — 15% evidence 17.6/20 RS sector 6.9% · RS bench 12.1% · 1Y 52.4%6 of 12 weeks ahead 100% evidence
Exact sum: 14.1 + 7.8 + 9.2 + 17.6 = 48.7 · Decision use: Price leads the evidence: RS versus the benchmark is 12.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
13Align Technology, Inc.ALGN 47.9/100Thin evidence · provisional58% evidence ASLEEP 17.0/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence 15.8/25 ROCE 3.5% · OPM 13.6% 76% evidence 10.4/20 P/E 29.3× · PEG — 15% evidence 4.7/20 RS sector -8.4% · RS bench -3.6% · 1Y 23.9%0 of 12 weeks ahead 100% evidence
Exact sum: 17 + 15.8 + 10.4 + 4.7 = 47.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14AptarGroup, Inc.ATR 47.3/100Thin evidence · provisional58% evidence TURNING 14.8/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence 15.2/25 ROCE 3.4% · OPM 10.9% 76% evidence 10.9/20 P/E 22.6× · PEG — 15% evidence 6.4/20 RS sector -8.6% · RS bench -4.2% · 1Y -3.2%2 of 12 weeks ahead 100% evidence
Exact sum: 14.8 + 15.2 + 10.9 + 6.4 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
15Warby Parker Inc.WRBY 45.8/100Thin evidence · provisional58% evidence FADING 15.9/35 Revenue 11.9% · PAT — · OPM change -0.4 pp 62% evidence 6.8/25 ROCE 0.3% · OPM 0.7% 76% evidence 8.5/20 P/E 1053.5× · PEG — 15% evidence 14.6/20 RS sector 4.2% · RS bench 9.4% · 1Y 28.2%4 of 12 weeks ahead 70% evidence
Exact sum: 15.9 + 6.8 + 8.5 + 14.6 = 45.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Medline Inc.MDLN 45.6/100Thin evidence · provisional51% evidence TURNING 13.1/35 Revenue 12.1% · PAT -12.5% · OPM change -2.9 pp 83% evidence 12.2/25 ROCE 1.2% · OPM 5.7% 76% evidence 10.3/20 P/E 32.6× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —0 of 12 weeks ahead 0% evidence
Exact sum: 13.1 + 12.2 + 10.3 + 10 = 45.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Repligen CorporationRGEN 45.1/100Thin evidence · provisional58% evidence BREAKING OUT 18.8/35 Revenue — · PAT — · OPM change 4.3 pp 45% evidence 10.3/25 ROCE 0.5% · OPM 8.2% 76% evidence 8.9/20 P/E 186.9× · PEG — 15% evidence 7.1/20 RS sector -6.8% · RS bench -2.5% · 1Y 34.4%7 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 10.3 + 8.9 + 7.1 = 45.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
18Stevanato Group S.p.A.STVN 44.4/100Mixed-negative evidence81% evidence FADING 19.0/35 Revenue 6.9% · PAT 12.7% · OPM change 0.7 pp 83% evidence 14.8/25 ROCE 2% · OPM 14.2% 76% evidence 7.1/20 P/E 23.3× · PEG 2.74 65% evidence 3.5/20 RS sector -14.8% · RS bench -10.9% · 1Y -16.8%9 of 12 weeks ahead 100% evidence
Exact sum: 19 + 14.8 + 7.1 + 3.5 = 44.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Bausch + Lomb CorporationBLCO 41.0/100Thin evidence · provisional58% evidence ASLEEP 20.9/35 Revenue — · PAT — · OPM change 10 pp 45% evidence 8.5/25 ROCE 0.7% · OPM 2.7% 76% evidence 8.6/20 P/E 775.5× · PEG — 15% evidence 3.0/20 RS sector -11.2% · RS bench -6.8% · 1Y 22.3%0 of 12 weeks ahead 100% evidence
Exact sum: 20.9 + 8.5 + 8.6 + 3 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
20DENTSPLY SIRONA Inc.XRAY 40.6/100Mixed-negative evidence64% evidence TURNING 8.9/35 Revenue -1% · PAT — · OPM change -11.2 pp 62% evidence 5.5/25 ROCE -0.8% · OPM -4% 76% evidence 11.0/20 P/E 22.6× · PEG — 15% evidence 15.2/20 RS sector 0.5% · RS bench 5.1% · 1Y 10.1%4 of 12 weeks ahead 100% evidence
Exact sum: 8.9 + 5.5 + 11 + 15.2 = 40.6 · Decision use: Price leads the evidence: RS versus the benchmark is 5.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
21Teleflex IncorporatedTFX 34.3/100Adverse evidence71% evidence TURNING 6.4/35 Revenue -32.4% · PAT -138.7% · OPM change -14.6 pp 83% evidence 8.9/25 ROCE 0.3% · OPM 3.7% 76% evidence 10.7/20 P/E 28× · PEG — 15% evidence 8.3/20 RS sector -2.1% · RS bench 2.8% · 1Y 18.3%4 of 12 weeks ahead 100% evidence
Exact sum: 6.4 + 8.9 + 10.7 + 8.3 = 34.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22Becton, Dickinson and CompanyBDX 33.9/100Adverse evidence81% evidence TURNING 12.7/35 Revenue 6.4% · PAT 4.8% · OPM change -6.5 pp 83% evidence 8.8/25 ROCE 0.2% · OPM 2% 76% evidence 8.7/20 P/E 39.8× · PEG 2.42 65% evidence 3.7/20 RS sector -17.1% · RS bench -13.4% · 1Y -12.1%2 of 12 weeks ahead 100% evidence
Exact sum: 12.7 + 8.8 + 8.7 + 3.7 = 33.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23Azenta, Inc.AZTA 30.1/100Thin evidence · provisional58% evidence BREAKING OUT 8.4/35 Revenue 2% · PAT — · OPM change -101.8 pp 62% evidence 4.4/25 ROCE -9.6% · OPM -114.5% 76% evidence 11.5/20 P/E 2.1× · PEG — 15% evidence 5.8/20 RS sector -9.3% · RS bench -5.5% · 1Y 3.8%3 of 12 weeks ahead 70% evidence
Exact sum: 8.4 + 4.4 + 11.5 + 5.8 = 30.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
24Alcon Inc.ALC 29.7/100Adverse evidence81% evidence TURNING 10.7/35 Revenue 7.1% · PAT -26.9% · OPM change -8.1 pp 83% evidence 9.9/25 ROCE 0% · OPM 10.8% 76% evidence 4.8/20 P/E 45.4× · PEG 6.35 65% evidence 4.3/20 RS sector -19.5% · RS bench -15.7% · 1Y -17.2%1 of 12 weeks ahead 100% evidence
Exact sum: 10.7 + 9.9 + 4.8 + 4.3 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25The Cooper Companies, Inc.COO 28.6/100Adverse evidence85% evidence TURNING 7.2/35 Revenue 6.1% · PAT -43.1% · OPM change -21.3 pp 95% evidence 7.8/25 ROCE -0.3% · OPM -2.9% 76% evidence 6.9/20 P/E 53.3× · PEG 2.6 65% evidence 6.7/20 RS sector -12.1% · RS bench -8% · 1Y 6.3%3 of 12 weeks ahead 100% evidence
Exact sum: 7.2 + 7.8 + 6.9 + 6.7 = 28.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26Pulse Biosciences, Inc.PLSE 54.3/100Thin evidence · provisional42% evidence BREAKING OUT 19.3/35 Revenue — · PAT — · OPM change 98992.5 pp 19% evidence 5.0/25 ROCE -19.4% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 20.0/20 RS sector 62.3% · RS bench 71.4% · 1Y 159.5%10 of 12 weeks ahead 100% evidence
Exact sum: 19.3 + 5 + 10 + 20 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27BioLife Solutions, Inc.BLFS 48.8/100Thin evidence · provisional47% evidence BREAKING OUT 17.8/35 Revenue — · PAT — · OPM change 2.4 pp 32% evidence 6.0/25 ROCE 0% · OPM 0.1% 76% evidence 8.7/20 P/E 228.4× · PEG — 15% evidence 16.3/20 RS sector 12.8% · RS bench 18.1% · 1Y 43.4%10 of 12 weeks ahead 70% evidence
Exact sum: 17.8 + 6 + 8.7 + 16.3 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28MiniMed Group, Inc.MMED 48.5/100Thin evidence · provisional44% evidence TURNING 24.1/35 Revenue 14.3% · PAT — · OPM change 9.3 pp 71% evidence 4.4/25 ROCE -2.5% · OPM -11.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y —4 of 9 weeks ahead 0% evidence
Exact sum: 24.1 + 4.4 + 10 + 10 = 48.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Alamar Biosciences, Inc.ALMR 41.2/100Thin evidence · provisional24% evidence TURNING 17.7/35 Revenue — · PAT — · OPM change 17.9 pp 13% evidence 3.5/25 ROCE -15.2% · OPM -47.4% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y —1 of 3 weeks ahead 0% evidence
Exact sum: 17.7 + 3.5 + 10 + 10 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
30Kestra Medical Technologies, Ltd.KMTS 41.0/100Thin evidence · provisional49% evidence TURNING 18.0/35 Revenue — · PAT — · OPM change -5.1 pp 45% evidence 3.6/25 ROCE -13.9% · OPM -141.6% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 9.4/20 RS sector -3.6% · RS bench 1% · 1Y 78.6%4 of 12 weeks ahead 70% evidence
Exact sum: 18 + 3.6 + 10 + 9.4 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Intuitive Surgical, Inc.'s stock price today?

Intuitive Surgical, Inc. trades at $368, −23.8% over the past year. The company is valued at $130 B. The stock sits at 12% of its 52-week range of $338–$586, −23.5% versus its 200-day average. On the tape, the price is in a downtrend, 28 weeks in. — as of 5 August 2026.

What were Intuitive Surgical, Inc.'s latest quarterly results?

Intuitive Surgical, Inc. reported revenue of $2.8 B and net profit of $0.8 B for the Mar 26 quarter. Revenue rose 23.1% and profit rose 18.6% year on year. Earnings per share were $2.28. The operating margin was 31.0%, 5.2 pp higher than a year earlier. — as of 5 August 2026.

What is Intuitive Surgical, Inc.'s revenue?

Intuitive Surgical, Inc. reported revenue of $2.8 B in the Mar 26 quarter, +23.1% year on year. For the full FY25 fiscal year, revenue was $10.1 B (+20.5%). Over the last 4 years revenue compounded at 15.2% a year. — as of 5 August 2026.

What is Intuitive Surgical, Inc.'s profit?

Intuitive Surgical, Inc. earned $0.8 B of net profit in the Mar 26 quarter, +18.6% year on year — the 12th straight quarter of growth. Full-year FY25 profit was $2.9 B. The operating margin ran 31.0% in the latest quarter. — as of 5 August 2026.

What is Intuitive Surgical, Inc.'s market cap?

Intuitive Surgical, Inc.'s market capitalisation is $130 B at a stock price of $368. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

What is Intuitive Surgical, Inc.'s P/E ratio?

Intuitive Surgical, Inc. trades at a P/E of 42.2×, at the 1st percentile of its own 4-year range, against a long-run median of 71.7×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.

Does Intuitive Surgical, Inc. pay a dividend?

No — Intuitive Surgical, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.

Is Intuitive Surgical, Inc. overvalued?

On its own history, Intuitive Surgical, Inc. looks cheap against its own history: its P/E of 42.2× has been cheaper only 1% of the time in 4 years (long-run median 71.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.

Is Intuitive Surgical, Inc. growing?

Yes — Intuitive Surgical, Inc. is growing: latest-quarter revenue +23.1% year on year, profit +18.6%, and the margin +5.2 pp at 31.0%. The 4-year compound rates are 15.2% (revenue) and 13.6% (profit). The earnings engine currently reads: improving — as of 5 August 2026.

How is Intuitive Surgical, Inc. performing?

Intuitive Surgical, Inc. is in a downtrend, 28 weeks in. Its latest quarter's revenue rose 23.1% and profit rose 18.6% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 29 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is Intuitive Surgical, Inc. in?

Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 17.9% and holding. The read comes from the last 12 quarters of growth (revenue growth +21.6% latest, profit growth +20.5% latest, eps growth +21.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is Intuitive Surgical, Inc. in an uptrend?

No — the price is in a downtrend (week 28 of stage 4), trading −23.5% versus its 200-day average and at 12% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is Intuitive Surgical, Inc. beating the market?

Not lately — on a trailing-13-week view Intuitive Surgical, Inc. is currently behind the S&P 500 (29 weeks and counting; last ahead the week of 2026-01-16), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +388% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.

Will Intuitive Surgical, Inc.'s stock price go up?

This page publishes no price forecast for Intuitive Surgical, Inc. What it measures instead: the stock price is $368, the price is in a downtrend 28 weeks in. Its P/E of 42.2× sits at the 1st percentile of its own 4-year range. — as of 5 August 2026.

Is the market betting against Intuitive Surgical, Inc.?

No — short interest is 1.9% of Intuitive Surgical, Inc.'s tradable float, about 2.4 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

What is Intuitive Surgical, Inc.'s capex?

Intuitive Surgical, Inc. spent $3.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.5 B. — as of 5 August 2026.

What is Intuitive Surgical, Inc.'s cash flow?

Intuitive Surgical, Inc. generated $3.0 B of operating cash flow in FY25 and $2.5 B of free cash flow after $0.5 B of capital spending. Reported profit that year was $2.9 B, so operating cash ran ahead of profit. — as of 5 August 2026.

Is Intuitive Surgical, Inc.'s profit real cash?

Yes — over the last 3 fiscal years, 103% of Intuitive Surgical, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $3.0 B against reported profit of $2.9 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.

How financially safe is Intuitive Surgical, Inc.?

On the balance sheet, the Z-score reads 42.45 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.

Where is Intuitive Surgical, Inc. in its business cycle?

Intuitive Surgical, Inc.'s FY25 operating margin was 29.3%, against a 5-year band of 24.9%–31.9%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 31.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Intuitive Surgical, Inc. story?

The sharpest disagreement: annual EPS moved +22.6% against a −23.8% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Intuitive Surgical, Inc. a stock worth studying right now?

This is not investment advice. The machine read: Intuitive Surgical, Inc.'s earnings have outrun its stock. EPS grew +22.6% in a year against a −23.8% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI